4.8 Review

Genome-wide association studies: progress and potential for drug discovery and development

期刊

NATURE REVIEWS DRUG DISCOVERY
卷 7, 期 3, 页码 221-230

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2519

关键词

-

资金

  1. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER
  2. NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066569] Funding Source: NIH RePORTER
  4. NCRR NIH HHS [P20 RR016480, P20 RR016480-07] Funding Source: Medline
  5. NIAID NIH HHS [U01AI066,569, U01 AI066569, U01 AI066569-03] Funding Source: Medline
  6. NICHD NIH HHS [U19 HD077693] Funding Source: Medline
  7. PHS HHS [N01A000,064] Funding Source: Medline

向作者/读者索取更多资源

Although genetic studies have been critically important for the identification of therapeutic targets in Mendelian disorders, genetic approaches aiming to identify targets for common, complex diseases have traditionally had much more limited success. However, during the past year, a novel genetic approach - genome-wide association ( GWA) - has demonstrated its potential to identify common genetic variants associated with complex diseases such as diabetes, inflammatory bowel disease and cancer. Here, we highlight some of these recent successes, and discuss the potential for GWA studies to identify novel therapeutic targets and genetic biomarkers that will be useful for drug discovery, patient selection and stratification in common diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据